Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Multi-modal intervention to reduce cardiovascular risk among hypertensive older adults: Design of a randomized clinical trial.

Buford TW, Anton SD, Bavry AA, Carter CS, Daniels MJ, Pahor M.

Contemp Clin Trials. 2015 Jul;43:237-42. doi: 10.1016/j.cct.2015.06.019. Epub 2015 Jun 23.

2.

Caveolin-1 prevents sustained angiotensin II-induced resistance artery constriction and obesity-induced high blood pressure.

Czikora I, Feher A, Lucas R, Fulton DJ, Bagi Z.

Am J Physiol Heart Circ Physiol. 2015 Mar 1;308(5):H376-85. doi: 10.1152/ajpheart.00649.2014. Epub 2014 Dec 19.

3.

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE, Davidson MH.

Endocr Pract. 2013 May-Jun;19(3):536-57. doi: 10.4158/EP13176.CS. No abstract available.

4.

The past, present and future of renin-angiotensin aldosterone system inhibition.

Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Piña IL, Fiuzat M, O'Connor CM, Zannad F, Pitt B.

Int J Cardiol. 2013 Sep 1;167(5):1677-87. doi: 10.1016/j.ijcard.2012.10.007. Epub 2012 Oct 31. Review.

5.

An emerging role of degrading proteinases in hypertension and the metabolic syndrome: autodigestion and receptor cleavage.

Schmid-Schönbein GW.

Curr Hypertens Rep. 2012 Feb;14(1):88-96. doi: 10.1007/s11906-011-0240-9. Review.

6.
7.

Increased availability of angiotensin AT 1 receptors leads to sustained arterial constriction to angiotensin II in diabetes - role for Rho-kinase activation.

Bagi Z, Feher A, Cassuto J, Akula K, Labinskyy N, Kaley G, Koller A.

Br J Pharmacol. 2011 Jul;163(5):1059-68. doi: 10.1111/j.1476-5381.2011.01307.x.

8.

Diabetes & coronary heart disease: current perspectives.

Ali MK, Narayan KM, Tandon N.

Indian J Med Res. 2010 Nov;132:584-97. Review.

9.

Combination therapy in hypertension: An update.

Kalra S, Kalra B, Agrawal N.

Diabetol Metab Syndr. 2010 Jun 24;2(1):44. doi: 10.1186/1758-5996-2-44.

10.

Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.

Cesari M, Kritchevsky SB, Atkinson HH, Penninx BW, Di Bari M, Tracy RP, Pahor M.

Am Heart J. 2009 Feb;157(2):334.e1-8. doi: 10.1016/j.ahj.2008.10.026.

11.

"Normal" blood glucose and coronary risk.

Barrett-Connor E, Wingard DL.

BMJ. 2001 Jan 6;322(7277):5-6. No abstract available.

Supplemental Content

Support Center